TGF-beta signaling in breast cancer

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 119-126

  Buck, Miriam B ^a   Knabbe, Cornelius ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Antiestrogen; Breast cancer; Growth inhibition; Metastasis; TGF beta

Indexed keywords

ANTIESTROGEN; BONE MORPHOGENETIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; SMAD PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR SUPPRESSOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRANSFORMING GROWTH FACTOR BETA;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CONFERENCE PAPER; DRUG EFFECT; GROWTH INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; DRUG RESISTANCE; FEMALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33847770211     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.024     Document Type: Conference Paper

References (31)

1. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
2. DICKSON, R.B. & M.E. LIPPMAN. 1995. Growth factors in breast cancer. Endocr. Rev. 16: 559-589.
3. HOUSTON, S.J., T.A. PLUNKETT, et al. 1999. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer 79: 1220-1226.
4. BUCK, M.B., K. PFIZENMAIER, et al. 2004. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol. Endocrinol. 18: 1643-1657.
5. KNABBE, C., M.E. LIPPMAN, et al. 1987. Evidence that transforming growth factorbeta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428.
6. KINGSLEY, D.M. 1994. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8: 133-146.
7. ANNES, J.P., J.S. MUNGER, et al. 2003. Making sense of latent TGFbeta activation. J. Cell. Sci. 116: 217-224.
8. ROBERTS, A.B. 1998. Molecular and cell biology of TGF-beta. Miner. Electrolyte Metab. 24: 111-119.
9. DE CAESTECKER, M. 2004. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev. 15: 1-11.
10. FENG, X.H. & R. DERYNCK.. 2005. Specificity and versatility in TGF-beta signaling through Smads. Annu. Rev. Cell. Dev. Biol. 21: 659-693.
11. MOUSTAKAS, A. & C.H. HELDIN. 2005. Non-Smad TGF-beta signals. J. Cell. Sci. 118: 3573-3584.
12. KNABBE, C., A. KOPP., et al. 1996. Regulation and role of TGF beta production in breast cancer. Ann. N.Y. Acad. Sci. 784: 263-276.
13. KNABBE, C., G. ZUGMAIER, et al. 1991. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am. J. Clin. Oncol. 14 (Suppl 2): S15-S20.
14. MULLER, V., E.V. JENSEN, et al. 1998. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res. 58: 263-267.
15. MACCALLUM, J., J.C. KEEN, et al. 1996. Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. Br. J. Cancer 74: 474-478.
16. BRANDT, S., A. KOPP, et al. 2003. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer. Anticancer Res. 23: 223-229.
17. KOPP, A., W. JONAT, et al. 1995. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res. 55: 4512-4515.
18. BUCK, M., J. VON DER FECHT, et al. 2002. Antiestrogenic regulation of transforming growth factor beta receptors I and II in human breast cancer cells. Ann. N.Y. Acad. Sci. 963: 140-143.
19. BASOLO, F., L. FIORE, et al. 1994. Response of normal and oncogenetransformed human mammary epithelial cells to transforming growth factor beta 1 (TGF-beta 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. Int. J. Cancer 56: 736-742.
20. ZUGMAIER, G., B.W. ENNIS, et al. 1989. Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J. Cell. Physiol. 141: 353-361.
21. GORSCH, S.M., V.A. MEMOLI, et al. 1992. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 52: 6949-6952.
22. MCEARCHERN, J.A., J.J. KOBIE, et al. 2001. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int. J. Cancer 91: 76-82.
23. BEISNER, J., M.B. BUCK, et al. 2006. A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer. Cancer Res. 66: 7554-7561.
24. BUCK, M.B., P. FRITZ, et al. 2004. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin. Cancer Res. 10: 491-498.
25. MATSUDA, T., T. YAMAMOTO, et al. 2001. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J. Biol. Chem. 276: 42908-42914.
26. BORG, A., B. BALDETORP, et al. 1994. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81: 137-144.
27. CARLOMAGNO, C., F. PERONE, et al. 1996. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 14: 2702-2708.
28. HOUSTON, S.J., T.A. PLUNKETT, et al. 1999. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer 79: 1220-1226.
29. WRIGHT, C., S. NICHOLSON, et al. 1992. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 65: 118-121.
30. SETON-ROGERS, S.E., Y. LU, et al. 2004. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc. Natl. Acad. Sci. USA 101: 1257-1262.
31. UEDA, Y., S. WANG, et al. 2004. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J. Biol. Chem. 279: 24505-24513.